ISRCTN63565713
Completed
未知
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depression
axdale Ltd (UK)0 sites0 target enrollmentFebruary 3, 2003
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- axdale Ltd (UK)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Written informed consent
- •2\. Diagnosis of major depressive disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth edition \[DSM\-IV])
- •3\. Score of between and including 16 and 25 on the Hamilton Depression Rating Scale (HDRS)
- •4\. No treatment with any antidepressant medication (including St John's Wort) in the last 12 weeks from the date of Visit 0 (screen)
- •5\. Male or female of any race aged 18\-75
Exclusion Criteria
- •Not provided at time of registration
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose ranging pilot study of ethyl eicosapentaenoate (EPA) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural DisordersISRCTN44366049axdale Ltd (UK)
Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled, dose-ranging pilot study of ethyl-eicosapentaenoate (ethyl-EPA) in patients with schizophreniaSchizophreniaMental and Behavioural DisordersISRCTN44218911axdale Ltd (UK)
Completed
Not Applicable
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) as adjunct therapy in patients who remain depressed following treatment with standard antidepressant therapyDepressionMental and Behavioural DisordersDepressive episodeISRCTN38354847axdale Ltd (UK)
Active, not recruiting
Not Applicable
Clinical study to investigate the efficacy and safety of an ointment that increases the blood circulation in the skin, containing 2.5% Nicoboxil and 0.4% Nonivamide, in comparison to ointments that contain only one of both compounds, or none of them (placebo) for the treatment of acute low back paiAcute low back painTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2011-003890-27-DEBoehringer Ingelheim Pharma GmbH & Co. KG
Active, not recruiting
Phase 1
Efficacy and safety study of benralizumab added to high-dose inhaled corticosteroid plus LABA in patients with uncontrolled asthmaEUCTR2013-002345-11-GBAstraZeneca AB1,134